At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 5, 2026 at 07:00 ET
Immatics reported full-year 2025 financial results with a significant revenue decline to $56.8 million and a net loss of $230.8 million, driven by the prior year's one-time collaboration revenue. The company maintains a strong cash position of $551.4 million, extending its runway into 2028, and continues to advance its PRAME-targeted oncology pipeline with key milestones expected in 2026 and 2027, including pivotal data readouts and BLA submission for anzu-cel in melanoma.
- Revenue declined to $56.8 million in 2025 from $183.1 million in 2024, primarily due to the absence of one-time collaboration revenue from Bristol Myers Squibb.
- Net loss was $230.8 million in 2025 compared to a net profit of $17.9 million in 2024.
- Cash and financial assets totaled $551.4 million as of December 31, 2025, following a $125 million public offering, supporting operations into 2028.
- Phase 3 SUPRAME trial for anzu-cel in melanoma remains on track with interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access